Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Part D’s Six Protected Drug Classes May Ride Baucus Medicare Vehicle

Executive Summary

A statutory requirement that Medicare Part D drug plans cover "all or substantially all" drugs in six classes stands a good chance of making it into the Senate Finance Committee's upcoming Medicare physician payment package

You may also be interested in...



Medicare Bill Allows Changes To Part D Protected Classes, Via Rule-Making

The new statutory requirement that Medicare drug plans cover all drugs in protected drug classes includes a hint of possible flexibility for interested stakeholders - the designated groups could be expanded or subtracted, though only through a formal regulatory process

Medicare Bill Allows Changes To Part D Protected Classes, Via Rule-Making

The new statutory requirement that Medicare drug plans cover all drugs in protected drug classes includes a hint of possible flexibility for interested stakeholders - the designated groups could be expanded or subtracted, though only through a formal regulatory process

E-Rx, Dialysis Bundling Are Likely Survivors Of Failed Medicare Doc Fix Bill

Electronic prescribing is among the handful of drug-related items likely to be revived when Finance Committee Chairman Max Baucus, D-Mont., recrafts his Medicare physician payment package to gain broader Senate support

Related Content

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel